IDEAYA Biosciences Inc (NAS:IDYA)
$ 26.75 -0.7 (-2.55%) Market Cap: 2.31 Bil Enterprise Value: 1.47 Bil PE Ratio: 0 PB Ratio: 1.96 GF Score: 30/100

IDEAYA Biosciences Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript

Sep 30, 2021 / 03:20PM GMT
Release Date Price: $25.49 (+2.41%)
Alethia Young
Cantor Fitzgerald - Analyst

Hi, everyone. It's Alethia Young here. I cover large cap, small and mid-cap biotech at Cantor. We have IDEAYA Biosciences. We have Yujiro Hata, who is the President and CEO; and we have Paul Stone, who is the SVP and CFO. We'll be doing a fireside chat for most of the conversation today.

Questions & Answers

Alethia Young
Cantor Fitzgerald - Analyst

So to start off, maybe can you just discuss IDEAYA's vision and how it originated? In general, what has the Company accomplished to date?

Yujiro Hata
IDEAYA Biosciences, Inc. - President and CEO

Sure, happy to. Thank you, Alethia, for the introduction and thank you to Cantor for the opportunity to participate today.

So IDEAYA was founded just over 6 years ago with a core focus to build the leading synthetic lethality-focused precision medicine oncology company. And since that time, we advanced two programs into the clinic: IDE397, which we believe is a potential best-in-class MAT2A inhibitor, targeting a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot